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Abstract 
Purpose: To investigate the effect of a combination of levocarnitine and iron saccharate on the 
treatment of renal anaemia and oxidative stress in patients undergoing haemodialysis. 
Methods: A total of 156 patients with renal anaemia were divided randomly into control (78 cases) and 
test groups (78 cases). Patients in the control group were treated with erythropoietin (EPO), iron 
saccharate, and conventional symptomatic treatment, while patients in the test group were treated with 
levocarnitine additionally. Anaemia indices, oxidative stress indices, response rate, and EPO dose were 
compared. 
Results: At week 28, the levels of hemoglobin b (Hb), hematocrit (Hct), serum ferritin (SF), and 
transferrin saturation (TSAT) in the test group were 92.72 ± 12.51 g/L, 34.74 ± 5.89 vol %, 245.61 ± 
81.35 ng/mL, and 24.34 ± 5.32 %, respectively, which were much lower than the levels in the test group 
(114.36 ± 12.27 g/L, 40.23 ± 5.78 vol %, 345.07 ± 85.93 ng/mL, and 29.76 ± 5.41 %, respectively; p < 
0.05). The levels of advanced oxidation protein products (AOPP) and malonaldehyde (MDA) in the test 
group were much higher than those of the control group (121.77 ± 31.65 nmol/L vs 89.65 ± 30.53 
nmol/L; 9.58 ± 2.64 nmol/L vs 4.81 ± 2.57 nmol/L, respectively (p < 0.05). EPO was maintained at a 
high dose from the beginning of treatment to week 28 in the control group, whereas in the test group, 
EPO dose was reduced gradually. The response rate in the test group was higher than that in the 
control group (92.30 % vs 76.90 %; p < 0.05). 
Conclusion: Levocarnitine/iron saccharate combination had a significant positive effect on the 
treatment of renal anaemia. It effectively relieved oxidative stress reactions and reduced the dose of 
EPO required. 
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Renal anaemia, a commonly observed 
complication in patients with chronic renal failure 
during the terminal stage, occurs when the 
glomerular filtration rate (GFR) is reduced by 
over 50 % [1,2]. Renal anaemia can induce 
abnormalities in multiple physiological functions, 
as well as cardiovascular and cerebrovascular 
diseases, thereby influencing the quality of life of 
patients with chronic kidney disease and 
lowering survival rates. Fortunately, 
erythropoietin (EPO) can relieve anaemic 
symptom in patients with chronic renal failure [3]. 
However, some patients with renal anaemia who 
undergo haemodialysis treatment respond poorly 
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or not at all to EPO because of iron deficiency, 
chronic infection, and malnutrition [4,5]. Thus, 
supplementing with iron saccharate is usually 
regarded as an adjuvant therapy. However, 
researchers [6,7] have found that iron saccharate 
can induce an increase in oxidative stress 
reactions and the occurrence of cardiovascular 
and cerebrovascular events. Thus, antioxidant 
interventions are also important in patients 
undergoing haemodialysis. 
 
Levocarnitine, also called L-carnitine [8], is an 
amino acid that is extensively distributed in body 
tissues and is used for the treatment of several 
chronic renal failure - associated complications in 
patients who undergo long-term haemodialysis 
and develop secondary carnitine deficiency. 
Levocarnitine can significantly relieve 
malnutrition and antioxidation, allowing the EPO 
dose to be lowered, thus reducing the economic 
stress on patients. This study evaluate the 
curative effect of iron saccharate combined with 
levocarnitine in renal anaemia and oxidative 
stress. To this end, the clinical effects of iron 
saccharate alone and iron saccharate in 
combination with levocarnitine were compared in 
treating chronic renal anaemia in patients 




Study setting, design and patient 
characteristics 
 
A total of 156 patients with renal anaemia who 
underwent haemodialysis between March 2011 
and June 2014 at Binzhou People’s Hospital, 
Shandong, China, were selected randomly. The 
study was approved by the Medical Ethics 
Committee of Binzhou People’s Hospital 
(approval number: CHX20150518BZ), and 
conformed to the principles of the Declaration of 
Helsinki [9]. Those with stable disease conditions 
for at least 1 month, who underwent 
haemodialysis 2 or 3 times per week, who had a 
haemoglobin (Hb) level < 90 g/L, a serum ferritin 
(SF) level < 200 ng/mL, or a transferrin 
saturation (TSAT) < 20 %, and who signed the 
informed consent form (themselves or a family 
member) were included. Those who suffered 
from other severe complications or endocrine 
diseases or who had been treated with 
chalybeate were excluded. 
 
The patients were divided into control (n = 78) 
and test (n = 78) groups using the random 
number table method. In the test group, there 
were 40 males and 38 females, with ages 
ranging from 34 to 66 years (average 49.46 ± 
10.13) and a haemodialysis period of 17.6 – 43.3 
months. In the control group, there were 42 
males and 36 females, with ages ranging from 35 
to 67 years (average 49.57 ± 9.97) and a 
haemodialysis period of 18.2 – 43.6 months. 
Age, gender, and duration of haemodialysis were 
not significantly different between the groups (p > 




Based on maintenance haemodialysis, patients 
in the control group were treated with EPO and 
iron saccharate. EPO (Chengdu Diao Jiuhong 
Pharmaceutical Co., Ltd., Sichuang, China; batch 
No.: S20020060) at doses 150 – 200 U/kg was 
injected subcutaneously. Hb levels were 
measured every 4 weeks. If the Hb level 
increased to < 10 g/L, then the EPO dose was 
increased by 25 U/kg each time; if the Hb level 
exceeded the normal value, then the EPO dose 
was decreased by 25 U/kg each time. Moreover, 
100 mg iron saccharate (Nanjing Hengsheng 
Pharmaceutical Co., Ltd., Jiangsu, China; batch 
no. H20113004) were injected through the vein 
end of the dialysis tube after each haemodialysis 
session. In the treatment group, the same 
procedure as that in the control group was 
followed, but the patients were additionally 
injected intravenously with 1.0 g levocarnitine 
(batch no. H20050443; Haiyue Pharmaceutical 
Co., Ltd, Jilin, China) and 20 mL normal saline 
after haemodialysis. Patients in both groups were 
treated for 28 weeks. 
 
Determination of parameters 
 
Levels of Hb, haematocrit (Hct), TSAT, advanced 
oxidation protein products (AOPP), and 
malonaldehyde (MDA) before treatment and after 
28 weeks of treatment were compared. The 
maintenance doses of EPO in the groups were 
recorded at the beginning of treatment and at 
weeks 14 and 28. The curative effect was 
determined according to the changes in the 
anaemia and oxidative indices [10]. The 
treatment was considered significantly effective if 
the Hb level improved to at least 30 g/L, the level 
of Hct increased to at least 0.1 vol %, or Hb and 
Hct both recovered to normal levels, and the 
anaemia symptoms improved significantly during 
treatment. The treatment was considered 
effective if the level of Hb improved to at least 15 
g/L or the Hct increased to at least 0.05 vol % 
and the anaemia symptoms were relieved by the 
end of treatment. The treatment was considered 
ineffective if the levels of Hb or Hct showed little 
to no change or the anaemia symptoms were 
aggravated. The formula for the overall response 
rate (R) is as in Eq 1.  
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R (%) = {(S + C)/T}100 ……………………… (1) 
 
S is the number of significantly effective cases, C 
the number of effective cases and T the total 




The SPSS software (ver. 19.0) was used for 
statistical analysis. Data expressed as mean ± 
standard deviation (SD), were analysed using the 
Student’s test. Numerical data were compared 
using the χ2 test. P values < 0.05 were 





Haematological and oxidative stress indices 
 
Levels of Hb, Hct, SF, TSAT, AOPP, and MDA in 
the two groups showed no statistically significant 
difference before treatment (all p > 0.05). After 
28 weeks of treatment, the levels of Hb, Hct, SF, 
and TSAT were significantly higher in the test 
group than the control group (p < 0.05), whereas 
the levels of AOPP and MDA were lower in the 
test group than in the control group (p < 0.05; 
Table 1). 
 
Comparison of EPO doses between the two 
groups 
 
Throughout the treatment period, the required 
EPO dose in the control group remained 
relatively high, whereas the EPO dose in the test 
group was reduced gradually. At week 28, the 
EPO dose in the test group was significantly 
lower than that in the control group (Table 2). 
 
Comparison of the curative effect between 
the two groups  
 
The results suggested that the overall response 
rate in the test group was significantly higher 
than that in the control group 24 h after treatment 
(p < 0.05; Table 3). 
 
Table 1: Comparison of haematological and oxidative stress indices between the two groups (mean ± SD) 
 
Parameter Time Control group Test group t P-value 
Hb(g/L) Before  74.87±14.30 75.33±14.88 0.128 0.899 After 92.72±12.51 114.36±12.27 7.766 0.000 
Hct(vol%) Before  21.93±4.32 21.42±4.50 0.484 0.629 After  34.74±5.89 40.23±5.78 4.185 0.000 
SF(ng/mL) Before  118.37±58.37 120.43±60.11 0.157 0.876 After 245.61±81.35 345.07±85.93 5.280 0.000 
TSAT(%) Before  17.24±3.92 17.33±3.93 0.091 0.928 After  24.34±5.32 29.76±5.41 4.480 0.000 
AOPP(nmol/L) Before  82.62±22.47 81.77±20.50 0.174 0.863 After 121.77±31.65 89.65±30.53 4.588 0.000 
MDA(nmol/L) Before  4.23±1.53 4.25±1.54 0.058 0.954 After  9.58±2.64 4.81±2.57 8.069 0.000 
Hb: haemoglobin B; Hct: hematocrit; SF: serum ferritin; TSAT: transferrin saturation; AOPP: advanced oxidation 
protein products; MDA: malonaldehyde; t: Student’s test; P: the appearance probability of specimen results or 
more extreme results when original hypothesis is true 
 
Table 2: Comparison of the erythropoietin dose between the two groups during treatment (mean ± SD, U/(kg·w)} 
 
Group Baseline Week 14 Week 28 
Control  185.70±14.90 179.30±12.60 160.20±12.30 
Treatment 183.40±15.60 163.10±11.70 142.10±12.50 
t 0.614 5.720 6.501 
P-value 0.541 0.000 0.000 
 
Table 3: Comparison of the response rate between the two groups (n) 
 
Group Significantly effective Effective Ineffective Response rate (%) 
Control  24 36 22 76.92 
Treatment  38 34 6 92.30* 
Note: * P < 0.05, vs. the control group 
 
  
Cui & Wu 




Renal anaemia is typically induced by chronic 
renal failure, caused by multiple organic renal 
diseases. The internal and external secretory 
functions of the kidney weaken or fail completely 
when chronic renal failure occurs. The 
pathogenesis of renal anaemia is complex. Its 
clinical manifestations are often masked by 
primary renal diseases, especially in the initial 
stages. 
 
With the extensive application of renal dialysis, 
patients with chronic renal failure now tend to 
have longer survival periods; however, the 
number of cases of chronic renal anaemia is also 
increasing [11]. A study [12] suggested that 
26.50 % and 95.80 % of 110 patients with 
chronic renal failure developed anaemia during 
the renal insufficiency period and the uraemia 
period, respectively. Most patients undergoing 
maintenance haemodialysis will likely develop 
chronic renal anaemia, and anaemia can 
severely influence treatment efficacy and quality 
of life. Therefore, there is an urgent need to treat 
chronic renal anaemia in patients undergoing 
maintenance haemodialysis. 
 
According to a previous study [13], EPO 
deficiency is the leading cause of chronic renal 
anaemia. Consequently, treating renal anaemia 
with EPO has been promoted in the early stages 
of the disease, and EPO can correct anaemia 
symptoms in most patients. However, recent 
clinical investigations suggest that about 10 % of 
patients with chronic renal anaemia show a poor 
response to EPO.  
 
A clinical study [14] showed that levels of Hb and 
Hct may fail to reach normal values after 
treatment with EPO. The main reason is that iron 
deficiency greatly influences the curative effect of 
EPO treatment. Indeed, half of haemodialysis 
patients undergoing EPO treatment experience a 
poor curative effect due to iron deficiency. 
Repeated blood collection, residual blood in the 
dialyzer or pipeline, and the application of high-
dose EPO can all result in iron deficiency. 
Moreover, iron in the storage pool may not be 
released in a timely manner, leading to a 
functional iron deficiency and a 
microinflammatory state [15]. As a result, 
chalybeate is usually given to renal anaemia 
patients undergoing haemodialysis during EPO 
treatment.  
 
Iron saccharate is an important drug used for iron 
supplementation. Sucrose molecules that 
surround Fe(OH)3, the core of iron saccharate, 
prevent its elimination by the kidney. However, 
studies [16,17] have suggested that iron 
saccharate can result in increased oxidative 
stress reactions, although it is considered safe 
and has a definite effect in treating renal 
anaemia. Oxidative stress refers to the release of 
a large number of oxygen radicals, caused by 
respiratory burst, which occurs when reduced 
coenzyme II on the membrane of leukocytes is 
activated.  
 
Levocarnitine, also called L-carnitine, is an amino 
acid that is extensively distributed in the body 
tissues and is necessary for the metabolism of 
fatty acids [18]. It has been shown that 
levocarnitine can promote the synthesis of 
albumins, significantly improve the stability of the 
erythrocyte membrane, increase Hct, and 
transport long-chain fatty acids into the body [19]. 
Patients undergoing maintenance haemodialysis 
tend to have insufficient levocarnitine, due to a 
lack of levocarnitine before treatment, severe 
loss during treatment, and the consumption of 
levocarnitine during treatment. Levocarnitine 
deficiency can affect metabolism, increase the 
fragility of normal red blood cells, and shorten the 
life of these cells [20]. 
 
This study found that the levels of two major 
oxidative stress markers, AOPP and MDA, were 
increased significantly in both groups before 
treatment, suggesting the presence of oxidative 
stress. After 28 weeks of treatment, the levels of 
AOPP and MDA increased markedly in both 
groups, indicating that iron saccharate resulted in 
a further increase in oxidative stress. However, 
the increases in the levels of AOPP and MDA 
were less in the test group than the control group 
at week 28 (p < 0.05), suggesting that 
levocarnitine had an antioxidant effect that could 
relieve the oxidative stress induced by iron 
saccharate.  
 
It was also found that the levels of Hb, Hct, SF, 
and TAST of the patients were higher in the test 
group than the control group at week 28. The 
dose of EPO in the test group, which was 
decreased gradually, was lower than that in the 
control group at week 28. This suggested that 
levocarnitine could improve the curative effect of 
EPO, and that the combined use could 
significantly relieve the anaemia symptoms of 
patients undergoing haemodialysis and lower the 
dose of EPO. The mechanism of action might be 
because levocarnitine promotes the absorption of 




No adverse reaction was observed in the 
research subjects, which differs from the findings 
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of other studies. It is considered that this was 
associated with the small sample size. Therefore, 
a study with a larger sample size is required to 
evaluate the safety of levocarnitine in 





Levocarnitine combined with iron saccharate has 
a positive therapeutic effect on renal anaemia in 
patients undergoing haemodialysis. The therapy 
significantly improves anaemia and oxidative 
stress indices and patient quality of life and 
reduces the damage caused by oxidative stress. 
However, the indications and conditions for 
administering the drugs must be established first, 
particularly in elderly patients whose physical 
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